Identifying causal genetic variants and understanding their mechanisms of effect on traits remains a challenge in genome-wide association studies (GWASs). In particular, how genetic variants (i.e., trans-eQTLs) affect expression of remote genes (i.e., trans-eGenes) remains unknown. We hypothesized that some trans-eQTLs regulate expression of distant genes by altering the expression of nearby genes (cis-eGenes). Using published GWAS datasets with 39,165 single-nucleotide polymorphisms (SNPs) associated with 1,960 traits, we explored whole blood gene expression associations of trait-associated SNPs in 5,257 individuals from the Framingham Heart Study. We identified 2,350 trans-eQTLs (at p < 10 À7 ); more than 80% of them were found to have cis-associated eGenes. Mediation testing suggested that for 35% of trans-eQTL-transeGene pairs in different chromosomes and 90% pairs in the same chromosome, the disease-associated SNP may alter expression of the transeGene via cis-eGene expression. In addition, we identified 13 trans-eQTL hotspots, affecting from ten to hundreds of genes, suggesting the existence of master genetic regulators. Using causal inference testing, we searched causal variants across eight cardiometabolic traits (BMI, systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, and fasting blood glucose) and identified several cis-eGenes (ALDH2 for systolic and diastolic blood pressure, MCM6 and DARS for total cholesterol, and TRIB1 for triglycerides) that were causal mediators for the corresponding traits, as well as examples of trans-mediators (TAGAP for LDL cholesterol). The finding of extensive evidence of genome-wide mediation effects suggests a critical role of cryptic gene regulation underlying many disease traits.
Introduction
Genome-wide association studies (GWASs) have identified tens of thousands of genetic variants associated with complex traits and diseases. 1, 2 Genetic variants identified by GWASs, however, explain only a small proportion of phenotypic variation, even for diseases known to have a strong genetic component, such as obesity, diabetes, and schizophrenia. 3, 4 This knowledge void has been termed the ''missing heritability.'' 5 One important consideration in the search for missing heritability is that the top GWAS single-nucleotide polymorphisms (SNPs) are often not causal variants for their associated traits, but rather are in linkage disequilibrium (LD) with causal SNPs. 3 In addition, fewer than 5% of GWAS SNPs are non-synonymous substitutions, while the remainder are located within non-coding regions. 2, 6 This suggests that instead of directly altering the amino acid sequence of proteins, SNPs can affect phenotypes by other mechanisms, such as regulation of gene transcription levels. Expression quantitative trait loci (eQTLs) are genetic variants that are associated with gene transcription levels. 7 eQTLs that alter expression of nearby transcripts (ciseGenes) are referred to as cis-eQTLs, whereas those associated with expression of remote transcripts (trans-eGenes), usually on different chromosomes, are referred to as trans-eQTLs. 8, 9 When SNPs at a trans-eQTL locus affect the expression of multiple trans-eGenes, the region is defined as a trans-eQTL hotspot. 10 cis-eQTLs typically reside close to transcription start sites (TSSs), suggesting that they directly impact gene expression. 11 In contrast to cis-eQTLs, analysis of trans-eQTLs is vastly more computationally challenging and reported trans-eQTLs have proven to be less replicable across studies. 11, 12 Therefore, many eQTL studies focus only on cis-eQTLs or a small subset of trans-eQTLs. 12,13 trans-eQTL hotspots are of particular interest because SNPs linked to such hotpots could serve important regulatory roles. The mechanisms by which trans-eQTLs alter transcription of their linked trans-eGenes are largely unknown and likely reflect indirect or cryptic regulation. 14, 15 For example, it has been proposed that expression of trans-eGenes could be mediated by transcription factors residing close to the corresponding trans-eQTLs. 14 This phenomenon would allow cis-eQTLs near regulatory genes to serve as master regulators for a large number of trans-eGenes. We found that some eQTLs can affect expression of eGenes both in a cis and trans manner, whereby cis-eGenes mediate the associations between eQTLs and trans-eGenes.
to identify cis-and trans-eQTLs and their associated eGenes. 17 Our results reveal that a large number of eQTLs regulate gene expression in both a cis and trans manner. Additionally, we identified 13 trans-eQTL hotspots and found that about one third of trans regulation is significantly mediated by the expression of cis-eGenes. As proof of principle, we inferred causality and directionality of SNP-transcript-trait relationships using genetic variants as instrumental variables in causal inference analyses. Specifically, we looked at eight cardiometabolic traits that were extensively characterized in the FHS, including body mass index (BMI), systolic and diastolic blood pressure, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, total cholesterol, and fasting blood glucose levels.
Material and Methods

Study Sample
In 1948, the FHS started recruiting participants (original cohort) from Framingham, MA, to begin the first round of physical examinations and lifestyle interviews to investigate cardiovascular disease (CVD) and its risk factors. In 1971 and 2002, FHS recruited offspring (and their spouses) and adult grandchildren of the original cohort participants into the Offspring and Third Generation cohorts, respectively. 18 A total of 5,257 participants from the FHS Offspring and Third Generation cohorts had gene expression profiling and genome-wide genotyping. 19 Methods for collection of whole blood samples and RNA isolation and preparation have been described previously. 19 A summary of the cardiometabolic traits used in this study can be found in Table S1 . All participants provided informed consent and the protocols were approved by the institutional review board. Figure 1 ).
Genotype Data
Gene Expression
Whole blood was collected in PAXgene tubes (PreAnalytiX) and frozen at À80 C. RNA was extracted using a whole blood RNA System Kit (QIAGEN) in FHS and mRNA expression profiling was assessed using the Affymetrix Human Exon 1.0 ST GeneChip platform (Affymetrix), which contains more than 5.5 million probes targeting the expression of 17,873 genes. The Robust Multi-array Average (RMA) package 21 was used to normalize gene expression values and remove any technical or spurious background variation. Linear regression models were used to adjust for technical covariates (batch, first principal component, and residual all probeset mean) and differential blood cell proportions. The pedigreemm package 22 was used to remove the effects of sex and age and accounted for familial relationships. 2,181 individuals from the Third Generation cohort had complete blood cell counts (white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils). Using gene expression data, we imputed the cell counts of remaining samples by partial least square (PLS) prediction that was developed in participants with measured cell counts and expression data. We did not find a significant difference when comparing results using imputed cell counts and those using measured values. Therefore, we used measured cell counts when they were available and used imputed values when measured cell counts were not available.
Identifying eQTLs and trans-eQTL Hotspots eQTL analysis was conducted on 5,257 individuals from the FHS Offspring and Third Generation cohorts using available mRNA expression data and genome-wide genotyping. Twenty PEER factors were calculated using a Bayesian framework and were used to account for hidden confounding factors in the adjusted gene expression data. 23 For each SNP-mRNA pair, a linear model was developed to identify SNP-mRNA associations, adjusting for PEER factors and familial relationship. p values were adjusted for multiple comparisons using the false discovery rate (FDR) ). Whole blood samples were collected from 5,257 FHS participants. Genome-wide genotyping and mRNA expression levels were assayed. We correlated 39,165 GWAS SNPs (after filtering) with expression levels of 17,873 genes to identify expression quantitative trait loci (eQTLs). For SNPs having both local (cis) and remote (trans) regulation effects, we then tested whether the effect of trans-eQTLs was mediated through cis-eGenes. Finally, integrating genotype, gene expression, and phenotype data, we conducted causal inference testing to identify causal variants for eight cardiometabolic traits (BMI, systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, fasting blood glucose).
method. 24 eQTLs at FDR % 0.05 were considered to be significant.
cis-eQTLs were defined as SNPs that reside within 1 Mb of the transcription start site. trans-eQTLs were defined as SNPs that were at a distance greater than 5 Mb from the TSS of an associated transcript on the same chromosome or on a different chromosome. eGenes were defined as genes associated with eQTLs. An independent set of eQTLs was obtained by pruning eQTLs in LD (R 2 > 0.2) and within 250 Kb, while keeping the most significant SNPs per eGene. trans-eQTL hotspots were identified by an index eQTL and nearby SNPs in high LD (R 2 > 0.8) associated with at least ten transeGenes. We excluded from analysis eQTLs that resided on the same chromosome but were less than 5 Mb from their eGenes to avoid confounding by long-range LD patterns.
Mediation and Causal Testing
Mediation testing was conducted using the mediation package (see Web Resources) in R with eQTL as the ''exposure,'' cis-eGene expression as the ''mediator,'' and trans-eGene expression as the ''outcome.'' A 100% proportion of mediation effect indicated that the entire association between an eQTL and expression of a transeGene (direct effect) is explained by effects of the eQTL on cis-eGene expression. Significant mediation effects were defined at a permutation threshold of p < 0.005 (1,000 permutations). The causal inference test (CIT) was conducted using the statistical package CIT 25 in R based on the following conditions: (1) the trait (T) is associated with the locus (L); (2) L is associated with the eGene mediator (G) after adjusting for T; (3) G is associated with T after adjusting for L; and (4) L is independent of T after adjusting for G. The p value of CIT is defined as the maximum of the four-component test p values by the intersection-union test framework ( Figure S1 ). 26 To determine whether cis-eGenes or trans-eGenes are causal mediators for a trait, CIT was performed for cis-eGenes and trans-eGenes separately. For a cis-eGene, we used its cis-eQTL with the smallest p value as an instrumental variable. For a trans-eGene, we calculated its best cis-eQTL from~8 million imputed SNPs residing within 1 Mb of the trans-eGene, based on the smallest p value.
Functional Annotation and Enrichment Testing
SNP annotations were conducted on HaploReg v.4.1, 27 which linked the SNPs with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE project, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. Regulatory motif enrichment was conducted using ciseQTLs residing in trans-eQTL hotspots as test sets and all cis-eQTLs as background. The gene ontology and transcription factor target enrichment analyses were conducted by ''Gene-Set Enrichment Analysis (GSEA).'' 28 The transcription factors (TFs) were extracted from FANTOM, 29 the large international consortium that mapped all human TFs and the genes they regulate; it contains 1,672 human genes. The protein-protein interaction (PPI) network contained a systematically generated or literature-curated dataset of~58,000 PPIs among 10,690 human proteins. 30 We defined hub proteins as those having no fewer than four interactions in the PPI network.
Results eQTLs Associated with Complex Disease Traits
At a minor allele frequency > 0.01 and imputation r 2 > 0.3, 39,165 genome-wide significant (p < 5 3 10 À8 ) SNPs reported in published GWAS databases 2 were genotyped or imputed in the FHS. At FDR < 0.05, we identified 23,579 cis-eQTLs (associated with expression of 2,933 ciseGenes at a corresponding p < 1 3 10 À4 ; Table S2 ) representing 5,974 independent SNPs (LD threshold < 0.2) and 2,350 trans-eQTLs (associated with expression of 606 trans-eGenes at a corresponding p < 1 3 10 À7 ; Table S3) representing 486 independent SNPs (LD threshold < 0.2). Because many SNPs in high LD are associated with different traits in GWASs, we used non-pruned eQTLs in the subsequent analyses. In total, we determined that 23,951 out of 39,165 (61%) statistically significant GWAS SNPs are eQTLs, which is consistent with previous findings that GWAS SNPs are enriched for eQTLs (p < 0.0001 for 10,000 random sets of 39,165 SNPs at MAF > 0.01 and r 2 > 0.3; average eQTL number ¼ 9,022).
13,31
Reproducibility and Mediation Effects of trans-eQTLs In accordance with previous results, 32 we found that trans effects on gene expression are much weaker than cis effects ( Figure S2A, (Table S4 ). The overlapping pairs increased to 562 (33%) when we used p < 1 3 10 À4 as our trans-eQTL threshold.
On the other hand, the replication rate was much higher for cis-eQTLs; 17,118 out of 38,608 (44%) cis-eQTL-ciseGene pairs in the Blood eQTL Browser were statistically significant (at p < 1 3 10 À4 ) in our results. Among them, 14,208 pairs (83%) had the same direction of effect. We hypothesized that the genetic effects of trans-eQTLs on expression of trans-eGenes are mediated in some cases by the expression of cis-eGenes (Figure 2 ). To test this hypothesis, we conducted mediation analyses for all 8,566 transeQTL-trans-eGene pairs to identify the proportion of the association between a trans-eQTL and trans-eGene that was attributable to the effect of the eQTL on cis-eGene expression. For trans-eQTLs and trans-eGenes on different chromosomes, we found that 1,953 out of 2,324 transeQTLs (84%) affect cis-eGene expression and that 2,612 trans-eQTL-trans-eGene pairs (35%) are significantly mediated by expression of cis-eGenes near the trans-eQTL. The proportion of mediation ranged from 1.4% to 100% (mean 15%). For trans-eQTLs and trans-eGenes on the same chromosome (by definition, separated by at least 5 Mb), we found that 913 out of 931 trans-eQTLs (98%) affect cis-eGene expression and that 1,011 trans-eQTLtrans-eGene pairs (90%) are significantly mediated by expression of cis-eGenes near the trans-eQTL, suggesting that trans-eGenes on the same chromosome are highly regulated through cis-eGenes (Table S5) .
trans-eQTL Hotspots
Among the 2,324 trans-eQTLs, we identified 13 transeQTL hotspots across eight chromosomes, with the index SNP associated with at least ten transcripts (Table 1 and Figure 3) . Notably, 8 out of 13 trans-eQTL hotspots were also identified in the Blood eQTL Browser, 12 Figure S2B ). We found that eGenes associated with trans-eQTL hotspots have a directional bias, with 65% of trans-eGenes showing the same directional effect in relation to the trans-eQTLs, rather than equal ratios of overexpression versus underexpression, as would be expected if the trans-eQTLs randomly affect the direction of expression of their corresponding trans-eGenes. For example, for age at menarche and HDL cholesterol, the associated trans-eGenes show 100% directionally consistent expression in relation to the index trans-eQTL (Table 1) . One explanation for this observation is that the trans-eQTL alters the activity or abundance of a transcription factor (TF, or other transacting factor), leading to concordant expression changes of all the target genes of this factor. For all 13 trans-eQTL hotspots, we found that 37% of trans-eQTL-trans-eGene associations were mediated by the expression of cis-eGenes (at p < 0.005 based on 1,000 bootstrap permutations, Figure 1 ). The strongest mediation effect was found at the NLRC5 locus on chromosome 16, which is associated with expression of ten eGenes at the HLA locus on chromosome 6. We found that 80% of the genetic effects between rs291040 and TAP1 are mediated by the cis expression of NLRC5 (Table 2) . Prior studies have shown that NLRC5 acts as a master regulator of MHC Figure 3 . trans-eQTL Hotspots x axis denotes the chromosomal location of SNPs. y axis denotes the number of trans-eGenes. Table 1 ) in 9 of 13 trans-eQTL hotspots. In addition, we found that 13 of 37 cis-eGenes shared the same regulatory motifs with the trans-eGene(s) of the same trans-hotspot, suggesting that both cis-eGene and trans-eGene are under the same regulatory control. The enriched functions of trans-eGenes are also highly consistent with the traits affected by the trans-eQTLs. For example, trans-eQTLs on chromosome 2 are associated with platelet count in GWASs. We found that the transeGenes in this hotspot are enriched for platelet degranulation (Table S8) . Moreover, analyzing 25 cis-eGenes having binary interactions identified in a systematic screen for protein-protein interactions (PPI), 30 we found that 15 of them are hub genes in the PPI network ( Figure S3 , p < 0.001 for randomly selecting 25 proteins in a PPI network), suggesting that cis-eGenes linked to trans-eQTLs play a central regulatory role in critical biological pathways through their mediation effects on trans-eGenes.
Causal Effects between eQTLs and Phenotypes
To test whether expression levels of eGenes (cis or trans) associated with eQTLs might explain the observed associations between eQTLs and phenotypes, we conducted causal inference testing (CIT) using the statistical package CIT in R. 25, 36 We applied this approach to the analysis of eight common cardiometabolic traits (BMI, blood lipid levels [HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol], fasting blood glucose, and systolic and diastolic blood pressure [SBP and DBP]) that were available along with genotype and gene expression data for 5,257 FHS participants. Among cis-eQTLs, we identified the SH2B3 (MIM: 605093)/ALDH2 (MIM: 100650) locus as having a causal effect on DBP (p ¼ 0.005) and SBP (p ¼ 0.02) through ALDH2 expression (Table 3) . SNPs in this locus are associated with coronary artery disease (CAD)/myocardial infarction (MI), blood pressure, LDLcholesterol, and type 1 diabetes (Figure 4 . Among trans-eQTLs, we identified the TAGAP locus as having a causal effect on LDL and total cholesterol through expression of TAGAP. The TAGAP locus has been found to be significantly associated with lipoprotein (a) levels 40 and TAGAP was reported to be differentially expressed in CAD patients 41 and after atorvastatin treatment. 42 Another possible mechanism to explain the association of trans-eQTLs with the expression of their trans-eGenes is reverse causality, whereby an eQTL alters expression of a trans-eGene through its effect on phenotype. In this case, the phenotype serves as a mediator (feedback effect). CIT, however, did not identify any examples of reverse causal effects (at p < 0.05).
Discussion
Identifying disease-causal genes and variants within GWASs results is an enormous challenge that simple association analysis cannot address. 43 Unlike GWASs, where the association between a genetic variant and trait is unidirectional, in transcriptome-wide association studies (TWASs) the direction of association between transcript and phenotype is not clear and causal inference must be drawn with caution. 44 eQTL studies hold the promise of revealing biological mechanisms of SNP-phenotype associations; integrating GWASs with TWASs may help prioritize genes and variants for functional studies. 44 In this study, we used a causal inference approach to infer causal relations and their directionality by integrating SNPs from GWASs with gene expression and phenotype data predicated on the assumption that if a gene is causally related to a phenotype, a nearby genetic variant (i.e., a cis-eQTL) that explains a large proportion of its expression should be associated with the same phenotype.
We discovered that many trans-eQTL-trans-eGene associations are mediated by cis-eGene expression, reflecting a complex regulatory mechanism. An intuitive explanation for hidden regulation of trans-eGenes is TFs that directly influence gene transcription. Although we found no enrichment for TFs among trans-eGenes, we found that more than one-third of cis-eGenes shared a common motif with trans-eGenes from the same trans-hotspot, indicating that there may exist indirect relations of cis-eGenes to TFs. For example, we identified trans-eGenes in the chromosome 7 hotspot that were enriched for the targets of TF PAX4 (MIM: 167413). The cis-eGene at this hotspot is TF IKZF1 and although PAX4 and IKZF1 are different TFs, they share common motifs.
Using different cell types and populations, Pierce et al. 15 also reported a similar proportion (~20%) of trans-eQTLs that act through cis-mediation, indicating that the mechanism of cis-eGene mediation of trans-eGene expression may be a common feature genome wide. To extend this concept, we explored how this phenomenon affects disease pathways. For example, we observed that rs174538, which was reported to be associated with plasma phospholipids in GWASs, 45 is a trans-eQTL of LDLR (MIM: 606945) expres-
). This association, however, was not significant after adjusting for expression of FADS2 (a ciseGene of rs174538) and the proportion of mediation of FADS2 (MIM: 606149) on LDLR was 100%. FADS2 is a key gene influencing n-3 polyunsaturated fatty acids (PUFA) levels and PUFA levels have been found to upregulate LDL receptor protein expression in fibroblasts and HepG2 cells, 46 indicating a likely pathway from PUFA to lipid metabolism. A recent study reported that Fads1 KO mice had 40% less atheromatous plaque compared to wild-type littermates. 47 Therefore, the FADS gene could be a putative therapeutic target for cardiovascular disease prevention and treatment.
We found that 10 out of 13 trans-eQTL hotspots are blood trait related and five of them replicated in the Blood eQTL Browser. 12 Among the 227 trans-eGenes associated with platelet SNPs, 26 were reported as platelet eQTLgenes, 48 suggesting that trans-eQTLs are highly tissue specific and that SNPs might remotely affect tissue-specific eGenes. For example, some of the loci identified in GWASs for platelet traits (e.g., ARHGEF3) affect the expression of hundreds of genes and may be key drivers of hematopoiesis and affect multiple blood cell lineages. 49 This study has several limitations. First, the Blood eQTL Browser 12 is the only database that includes extensive trans-eQTL results in a comparable large sample size. Therefore, our results cannot readily be validated in other tissues as most other large eQTL databases provide only cis-eQTLs. Second, although ours is one of the largest studies to detect trans-eQTLs, we are still underpowered for causal inference testing, which tests the SNP-phenotype association as the first condition. Therefore, many genes were excluded from causality testing because they did not fulfill the first condition. In summary, we provide evidence of a cis-mediated mechanism that explains distal regulation of trans-eGenes by their trans-eQTLs. Importantly, the causal loci, especially the trans-eQTLs identified from our integrative genomic approach, could not be detected from traditional GWASs by searching SNPs around the GWAS signal. Our next steps are to explore eQTL data from more diseaserelated tissues and to incorporate whole-genome sequence data to identify more causal eQTLs. We speculate that it may be worthwhile to apply this approach across eQTL databases and across multiple phenotypes as a means of identifying plausible targets for therapeutic intervention.
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